SCI时时刷

search
+
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
BRAF/MEK targeted therapies and immune checkpoint inhibition have dramatically improved disease control and survival of pa...
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new antic...
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma
I sincerely apologize for the misuse of images for tube formation assay (Fig. 5C, D) in the paper titled “KIF4A is a poten...
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
T cells are important components in the cell-mediated antitumour response. In recent years, bispecific antibodies (Bi-Abs)...
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
HLX22 is a novel monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). This first-in-human, phase...
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
Clinical trials on icotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), hav...
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth
Glioblastomas (GBM), also known as glioblastoma multiforme, are the most aggressive type of brain cancer. Currently, there...
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles
No report has assessed the differences in adverse event (AE) profiles of anticancer drugs for all types of cancers in clin...
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USADanny N. KhalilParker Institute for Cancer ...
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
Talazoparib, a poly(ADP-ribose) polymerase inhibitor, has demonstrated efficacy in the treatment of advanced breast and pr...
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In th...
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated do...
Prospective role of liquid biopsy for early screening in laryngeal cancer
Prospective role of liquid biopsy for early screening in laryngeal cancer
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worl...
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advance...
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
Hepatocellular carcinoma ranks fourth in cancer-related causes of death worldwide and second in China. Patients with hepat...
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase
Lung cancer is the leading cause of cancer-related deaths worldwide. Combination of drugs targeting independent signaling ...
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
Background: Prognosis for patients with metastatic melanoma has been improved dramatically with the development of BRAF/ME...
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study
The majority of melanoma patients experience relapse during adjuvant therapy or after the end of therapy. Sixty-one patien...
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor rec...
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
Soluble interleukin-2 receptor (sIL-2R) suppresses effector T-cells. Few studies have assessed serum sIL-2R in patients re...
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, P...
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung...
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
Ethics approval and consent to participate Since the study is based...
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
B7 homolog 3 protein (B7-H3), an immune checkpoint molecule belonging to the B7 family, has been studied as a target for t...
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Despite remarkable initial responses of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive non-small cell lung ca...
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitoge...
Mesenchymal stem cells: a trojan horse to treat glioblastoma
Mesenchymal stem cells: a trojan horse to treat glioblastoma
Glioblastoma multiforme (GBM) is the most common and lethal primary tumor of the central nervous system. What makes it so ...
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies....
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis
Background: To investigate the clinical features of nivolumab-induced myasthenia gravis (MG) and provide evidence for the ...
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
This study aimed to describe the real-world efficacy and safety of the combination therapy of atezolizumab and bevacizumab...
阅读更多
format_indent_increase